ºÝºÝߣshows by User: IMSHealth1 / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: IMSHealth1 / Sat, 13 May 2017 00:27:55 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: IMSHealth1 QuintilesIMS España: Impacto sobre el mercado farmacéutico del borrador Orden SSI/ /2017, de abril https://es.slideshare.net/slideshow/quintilesims-espaa-impacto-sobre-el-mercado-farmacutico-del-borrador-orden-ssi-2017-de-abril/75934954 impactooprabril2017-170513002755
En QuintilesIMS España hemos elaborado un análisis que permite calcular el impacto que tiene la aplicación del borrador OrdenSSI/ /2017, de abril, sobre el mercado farmacéutico. Para realizar este análisis se ha tomado como referencia el volumen de unidades vendido en el periodo Abril 2016-Marzo 2017.]]>
En QuintilesIMS España hemos elaborado un análisis que permite calcular el impacto que tiene la aplicación del borrador OrdenSSI/ /2017, de abril, sobre el mercado farmacéutico. Para realizar este análisis se ha tomado como referencia el volumen de unidades vendido en el periodo Abril 2016-Marzo 2017.]]> Sat, 13 May 2017 00:27:55 GMT https://es.slideshare.net/slideshow/quintilesims-espaa-impacto-sobre-el-mercado-farmacutico-del-borrador-orden-ssi-2017-de-abril/75934954 IMSHealth1@slideshare.net(IMSHealth1) QuintilesIMS España: Impacto sobre el mercado farmacéutico del borrador Orden SSI/ /2017, de abril IMSHealth1 En QuintilesIMS España hemos elaborado un análisis que permite calcular el impacto que tiene la aplicación del borrador OrdenSSI/ /2017, de abril, sobre el mercado farmacéutico. Para realizar este análisis se ha tomado como referencia el volumen de unidades vendido en el periodo Abril 2016-Marzo 2017. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/impactooprabril2017-170513002755-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> En QuintilesIMS España hemos elaborado un análisis que permite calcular el impacto que tiene la aplicación del borrador OrdenSSI/ /2017, de abril, sobre el mercado farmacéutico. Para realizar este análisis se ha tomado como referencia el volumen de unidades vendido en el periodo Abril 2016-Marzo 2017.
from QuintilesIMS
]]> 1441 2 https://cdn.slidesharecdn.com/ss_thumbnails/impactooprabril2017-170513002755-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Growth in the OTC Market /slideshow/growth-in-the-otc-market/74823612 consumerhealthinvestus2017infographic-170410150750
Key factors influencing the OTC market from September 2015 to September 2016]]>
Key factors influencing the OTC market from September 2015 to September 2016]]> Mon, 10 Apr 2017 15:07:50 GMT /slideshow/growth-in-the-otc-market/74823612 IMSHealth1@slideshare.net(IMSHealth1) Growth in the OTC Market IMSHealth1 Key factors influencing the OTC market from September 2015 to September 2016 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/consumerhealthinvestus2017infographic-170410150750-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Key factors influencing the OTC market from September 2015 to September 2016
Growth in the OTC Market from QuintilesIMS
]]> 302 3 https://cdn.slidesharecdn.com/ss_thumbnails/consumerhealthinvestus2017infographic-170410150750-thumbnail.jpg?width=120&height=120&fit=bounds infographic Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Channel preference & the road to multichannel maturity /slideshow/channel-preference-the-road-to-multichannel-maturity/72555566 qimultichannelmaturityandchannelpreferencemarch2017final-170224214119
Channel preference insight is only a guide on the road to multichannel maturity, but this insight is one of the most important starting points. ]]>
Channel preference insight is only a guide on the road to multichannel maturity, but this insight is one of the most important starting points. ]]> Fri, 24 Feb 2017 21:41:18 GMT /slideshow/channel-preference-the-road-to-multichannel-maturity/72555566 IMSHealth1@slideshare.net(IMSHealth1) Channel preference & the road to multichannel maturity IMSHealth1 Channel preference insight is only a guide on the road to multichannel maturity, but this insight is one of the most important starting points. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/qimultichannelmaturityandchannelpreferencemarch2017final-170224214119-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Channel preference insight is only a guide on the road to multichannel maturity, but this insight is one of the most important starting points.
Channel preference & the road to multichannel maturity from QuintilesIMS
]]> 864 2 https://cdn.slidesharecdn.com/ss_thumbnails/qimultichannelmaturityandchannelpreferencemarch2017final-170224214119-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The State of Oncology Innovation /slideshow/the-state-of-oncology-innovation/64812092 ims-036globaloncologyinfographicfl-160808201735
New science is redefining cancer as a large number of narrowly defined diseases and bringing therapeutic options to an expanded number of patients. With the rapid growth in the oncology treatment landscape, health systems are struggling to adapt and embrace the evolution—including regulatory systems, diagnostic infrastructure, treatment providers and financing mechanisms. These challenges will require urgent attention in light of the strong near-term pipeline of clinically distinctive therapies and new programs that are galvanizing research efforts to change the trajectory for cancer. Read the full report >> http://imsh.co/2axszmt]]>
New science is redefining cancer as a large number of narrowly defined diseases and bringing therapeutic options to an expanded number of patients. With the rapid growth in the oncology treatment landscape, health systems are struggling to adapt and embrace the evolution—including regulatory systems, diagnostic infrastructure, treatment providers and financing mechanisms. These challenges will require urgent attention in light of the strong near-term pipeline of clinically distinctive therapies and new programs that are galvanizing research efforts to change the trajectory for cancer. Read the full report >> http://imsh.co/2axszmt]]> Mon, 08 Aug 2016 20:17:34 GMT /slideshow/the-state-of-oncology-innovation/64812092 IMSHealth1@slideshare.net(IMSHealth1) The State of Oncology Innovation IMSHealth1 New science is redefining cancer as a large number of narrowly defined diseases and bringing therapeutic options to an expanded number of patients. With the rapid growth in the oncology treatment landscape, health systems are struggling to adapt and embrace the evolution—including regulatory systems, diagnostic infrastructure, treatment providers and financing mechanisms. These challenges will require urgent attention in light of the strong near-term pipeline of clinically distinctive therapies and new programs that are galvanizing research efforts to change the trajectory for cancer. Read the full report >> http://imsh.co/2axszmt <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ims-036globaloncologyinfographicfl-160808201735-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> New science is redefining cancer as a large number of narrowly defined diseases and bringing therapeutic options to an expanded number of patients. With the rapid growth in the oncology treatment landscape, health systems are struggling to adapt and embrace the evolution—including regulatory systems, diagnostic infrastructure, treatment providers and financing mechanisms. These challenges will require urgent attention in light of the strong near-term pipeline of clinically distinctive therapies and new programs that are galvanizing research efforts to change the trajectory for cancer. Read the full report &gt;&gt; http://imsh.co/2axszmt
The State of Oncology Innovation from QuintilesIMS
]]> 12311 8 https://cdn.slidesharecdn.com/ss_thumbnails/ims-036globaloncologyinfographicfl-160808201735-thumbnail.jpg?width=120&height=120&fit=bounds infographic Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Global Medicines Use in 2020:� Outlook and Implications /IMSHealth1/global-medicines-use-in-2020-outlook-and-implications institutereportglobalmedicine-160511201328
The global use of medicines will reach 4.5 trillion doses by 2020 costing $1.4 trillion. The largest pharmaceutical-using countries will be the pharmerging markets, accounting for two-thirds of the global medicine volumes, mostly comprised of generic medicines and reflecting dramatic increases in utilization of medicines due to broad-based health system expansions. Medicines in 2020 will include a vast array of treatments ranging from those that provide symptom relief available without a prescription to lifesaving genetically personalized therapies unique to a single patient. Disease treatments in 2020 will be transformed by the increased number and quality of new medicines in clusters of innovation around cancer, Hepatitis C, autoimmune disorders, heart disease and an array of rare diseases. By 2020, technology will be enabling more rapid changes to treatment protocols, increasing patient engagement and accountability, shifting patient-provider interaction, and accelerating the adoption of behavior changes that will improve patient adherence to treatments. ]]>
The global use of medicines will reach 4.5 trillion doses by 2020 costing $1.4 trillion. The largest pharmaceutical-using countries will be the pharmerging markets, accounting for two-thirds of the global medicine volumes, mostly comprised of generic medicines and reflecting dramatic increases in utilization of medicines due to broad-based health system expansions. Medicines in 2020 will include a vast array of treatments ranging from those that provide symptom relief available without a prescription to lifesaving genetically personalized therapies unique to a single patient. Disease treatments in 2020 will be transformed by the increased number and quality of new medicines in clusters of innovation around cancer, Hepatitis C, autoimmune disorders, heart disease and an array of rare diseases. By 2020, technology will be enabling more rapid changes to treatment protocols, increasing patient engagement and accountability, shifting patient-provider interaction, and accelerating the adoption of behavior changes that will improve patient adherence to treatments. ]]> Wed, 11 May 2016 20:13:28 GMT /IMSHealth1/global-medicines-use-in-2020-outlook-and-implications IMSHealth1@slideshare.net(IMSHealth1) Global Medicines Use in 2020:� Outlook and Implications IMSHealth1 The global use of medicines will reach 4.5 trillion doses by 2020 costing $1.4 trillion. The largest pharmaceutical-using countries will be the pharmerging markets, accounting for two-thirds of the global medicine volumes, mostly comprised of generic medicines and reflecting dramatic increases in utilization of medicines due to broad-based health system expansions. Medicines in 2020 will include a vast array of treatments ranging from those that provide symptom relief available without a prescription to lifesaving genetically personalized therapies unique to a single patient. Disease treatments in 2020 will be transformed by the increased number and quality of new medicines in clusters of innovation around cancer, Hepatitis C, autoimmune disorders, heart disease and an array of rare diseases. By 2020, technology will be enabling more rapid changes to treatment protocols, increasing patient engagement and accountability, shifting patient-provider interaction, and accelerating the adoption of behavior changes that will improve patient adherence to treatments. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/institutereportglobalmedicine-160511201328-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The global use of medicines will reach 4.5 trillion doses by 2020 costing $1.4 trillion. The largest pharmaceutical-using countries will be the pharmerging markets, accounting for two-thirds of the global medicine volumes, mostly comprised of generic medicines and reflecting dramatic increases in utilization of medicines due to broad-based health system expansions. Medicines in 2020 will include a vast array of treatments ranging from those that provide symptom relief available without a prescription to lifesaving genetically personalized therapies unique to a single patient. Disease treatments in 2020 will be transformed by the increased number and quality of new medicines in clusters of innovation around cancer, Hepatitis C, autoimmune disorders, heart disease and an array of rare diseases. By 2020, technology will be enabling more rapid changes to treatment protocols, increasing patient engagement and accountability, shifting patient-provider interaction, and accelerating the adoption of behavior changes that will improve patient adherence to treatments.
Global Medicines Use in 2020: Outlook and Implications from QuintilesIMS
]]> 32406 7 https://cdn.slidesharecdn.com/ss_thumbnails/institutereportglobalmedicine-160511201328-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The Essential European Revolution /slideshow/the-essential-european-revolution/60875513 europeanevolutioninfographic-160413164348
As companies seek maturity in multichannel commercial models, there’s one key problem for those operating in Europe: European countries lag behind the US and Japan significantly in terms of the volume share and relative impact of digital contacts with prescribers - and whilst digital is by no means the entirety of multichannel, it’s impossible to imagine a mature model without it.]]>
As companies seek maturity in multichannel commercial models, there’s one key problem for those operating in Europe: European countries lag behind the US and Japan significantly in terms of the volume share and relative impact of digital contacts with prescribers - and whilst digital is by no means the entirety of multichannel, it’s impossible to imagine a mature model without it.]]> Wed, 13 Apr 2016 16:43:48 GMT /slideshow/the-essential-european-revolution/60875513 IMSHealth1@slideshare.net(IMSHealth1) The Essential European Revolution IMSHealth1 As companies seek maturity in multichannel commercial models, there’s one key problem for those operating in Europe: European countries lag behind the US and Japan significantly in terms of the volume share and relative impact of digital contacts with prescribers - and whilst digital is by no means the entirety of multichannel, it’s impossible to imagine a mature model without it. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/europeanevolutioninfographic-160413164348-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> As companies seek maturity in multichannel commercial models, there’s one key problem for those operating in Europe: European countries lag behind the US and Japan significantly in terms of the volume share and relative impact of digital contacts with prescribers - and whilst digital is by no means the entirety of multichannel, it’s impossible to imagine a mature model without it.
The Essential European Revolution from QuintilesIMS
]]> 16042 5 https://cdn.slidesharecdn.com/ss_thumbnails/europeanevolutioninfographic-160413164348-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 IMS Health Clinical Trial Optimization Solutions /slideshow/ims-health-clinical-trial-optimization-solutions/40501571 imshealthclinicaltrialoptimizationsolutions-141020124052-conversion-gate02
IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA]]>
IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA]]> Mon, 20 Oct 2014 12:40:52 GMT /slideshow/ims-health-clinical-trial-optimization-solutions/40501571 IMSHealth1@slideshare.net(IMSHealth1) IMS Health Clinical Trial Optimization Solutions IMSHealth1 IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/imshealthclinicaltrialoptimizationsolutions-141020124052-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> IMS Health&#39;s Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment &amp; Retention Summit 2014 - San Francisco, CA
IMS Health Clinical Trial Optimization Solutions from QuintilesIMS
]]> 5115 12 https://cdn.slidesharecdn.com/ss_thumbnails/imshealthclinicaltrialoptimizationsolutions-141020124052-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-IMSHealth1-48x48.jpg?cb=1523694389 www.quintilesims.com https://cdn.slidesharecdn.com/ss_thumbnails/impactooprabril2017-170513002755-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/quintilesims-espaa-impacto-sobre-el-mercado-farmacutico-del-borrador-orden-ssi-2017-de-abril/75934954 QuintilesIMS España: I... https://cdn.slidesharecdn.com/ss_thumbnails/consumerhealthinvestus2017infographic-170410150750-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/growth-in-the-otc-market/74823612 Growth in the OTC Market https://cdn.slidesharecdn.com/ss_thumbnails/qimultichannelmaturityandchannelpreferencemarch2017final-170224214119-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/channel-preference-the-road-to-multichannel-maturity/72555566 Channel preference &amp; t...